27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The major neuropathological hallmarks of Alzheimer's disease (AD) are amyloid β (Aβ) plaques and neurofibrillary tangles (NFT), accompanied by neuroinflammation and neuronal loss. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Huntington's disease is a neurodegenerative disorder involving psychiatric, cognitive and motor symptoms. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This scientific commentary refers to ‘Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline’ by Rabin et al. (https://doi.org/10.1093/brain/awac178). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Synaptic dysfunction is an early mechanism in Alzheimer's disease that involves progressively larger areas of the brain over time. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The final cohort consisted of 91 302 Medicare beneficiaries with an ADRD diagnosis. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Residents in memory-care assisted living had a lower adjusted risk of hospitalization (risk difference = -1.8 percentage points [P = .014], hazard ratio = 0.93 [0.87-1.00]), a lower risk of nursing-home admission (risk difference = -2.2 percentage points [P < .001], hazard ratio = 0.87 [-.79-0.95]), and a lower risk of a long-term nursing home admission (risk difference = -1.1 percentage points [P < .001], hazard ratio = 0.71 [0.57-0.88]). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Disparities in incidence of NDD between Black and White beneficiaries narrowed by 0.37 per 100 person-years from 2014 to 2017. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From 2010 to 2016, the incidence and prevalence rates of LBD among Medicare beneficiaries ranged from 0.21%-0.18% and 0.90%-0.83%, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Of 439,760 HCV patients, the incidence rate of ADRD was higher in patients with periodontal diseases compared to those without (10.84% versus 9.26%, p < 0.001), and those with periodontal disease developed ADRD earlier compared to those without periodontal disease (13.99 versus 21.60 months, p < 0.001). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Quantification results using the proposed deep learning-based method showed stronger correlations with the FreeSurfer estimates than SPM-based SN using MRI did. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using amyloid PET imaging as a single primary surrogate efficacy measure in Alzheimer's disease immunotherapy trials, as happened when the FDA granted accelerated approval of aducanumab, is unjustified. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (SVD) causes lacunar stroke and vascular cognitive impairment in older people. 1 key finding →
Participants: 52 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular risk factors and lifestyle factors are associated with an increased risk of cognitive decline and dementia in observational studies, and have been targeted by multidomain interventions. 5 key findings →
Participants: 4,162 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Poor adherence to drug dosing schedule is responsible for ∼50% of hospitalization cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
New research shows that disease-associated microglia in neurodegenerative brains present features of elevated phagocytosis, lysosomal functions, and lipid metabolism, which benefit brain repair. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Microglial polarization plays an essential role in the progression and regression of neurodegenerative disorders. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Tumor-associated macrophages (TAMs) represent a key component of the tumor microenvironment and are generally associated with immunosuppression and poor prognosis. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Microglia, the resident phagocytes of the retina, are believed to influence the development of retinopathy, but their exact contributions to vascular integrity and neuronal loss are unknown. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Technology offers opportunities to support older adults with mild cognitive impairments to remain independent and socially connected, but is often not used. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Incorporating AD blood tests into screening for AD clinical trials may reduce the time and financial cost of enrollment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS) is a complex genetic condition due to an additional copy of human chromosome 21, which results in the deregulation of many genes. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our comprehensive search yielded 5 eligible studies. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →